---

$4.88

N/A ( 0% ) 0.1K

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-02-05	Sale	-337500.00	HAUSMAN DIANA
2024-02-05	Sale	-141000.00	Lackner Mark
2024-02-05	Sale	-112500.00	Paul Andrea
2024-02-05	Sale	-75000.00	Epperly Melissa B,
2024-02-05	Sale	-250000.00	Blackwell Kimberly
2024-01-03	Sale	-40000.00	Lackner Mark
2023-12-21	Sale	-24158.00	Bunker Kevin D.
2023-11-13	Buy	17000.00	Johnson David Michael
2023-11-13	Buy	5000.00	Blackwell Kimberly
2023-10-06	Sale	-8906.00	Brownstein Carrie